A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard […]
eNTRyway is our web app for predicting compound accumulation in Gram-negative bacteria. It predicts the likelihood of a small-molecule to accumulate in Gram-negative bacteria. This prediction is based on the presence of a suitable ionizable nitrogen, proper shape, and flexibility. Try the app here.
We congratulate Dr. Sarah Tasker on being awarded a postdoctoral fellowship from the Damon Runyon Cancer Research Foundation.
Human trials of cancer drug PAC-1 continue with new investment. University of Illinois chemistry professor Paul Hergenrother, right, and veterinary clinical medicine professor Timothy Fan tested an anti-cancer compound in pet dogs that is now being used in human clinical trials.
See listing on clinicaltrials.gov, listen to the interview, watch a PBS documentary about comparative oncology including PAC-1, and watch the CBS Chicago report.
We congratulate Sarah Perlmutter for receiving a NSF Predoctoral Graduate Research Fellowship!
Evi Llabani receives the inaugural C*Star Fellowship from the Cancer Center at Illinois.
Cancer drug tested in pet dogs is now bound for human trials. University of Illinois chemistry professor Paul Hergenrother, left, and veterinary clinical medicine professor Tim Fan led a study of an anti-cancer compound in pet dogs that is now headed for human clinical trials. Continue reading the Illinois News Bureau article.